(Q41612476)

English

Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification

scientific article published on 19 April 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 October 2017

Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification (English)

1 reference

Europe PubMed Central

5 October 2017

1 reference

based on heuristic

inferred from title

esophageal cancer

1 reference

based on heuristic

inferred from title

author name string

Yongxin Ren

1

1 reference

Europe PubMed Central

5 October 2017

Jianming Zheng

2

1 reference

Europe PubMed Central

5 October 2017

Shiming Fan

3

1 reference

Europe PubMed Central

5 October 2017

Linfang Wang

4

1 reference

Europe PubMed Central

5 October 2017

Min Cheng

5

1 reference

Europe PubMed Central

5 October 2017

Dongxia Shi

6

1 reference

Europe PubMed Central

5 October 2017

Wei Zhang

7

1 reference

Europe PubMed Central

5 October 2017

Renxiang Tang

8

1 reference

Europe PubMed Central

5 October 2017

Ying Yu

9

1 reference

Europe PubMed Central

5 October 2017

Longxian Jiao

10

1 reference

Europe PubMed Central

5 October 2017

Jun Ni

11

1 reference

Europe PubMed Central

5 October 2017

Haibin Yang

12

1 reference

Europe PubMed Central

5 October 2017

Huaqing Cai

13

1 reference

Europe PubMed Central

5 October 2017

Fang Yin

14

1 reference

Europe PubMed Central

5 October 2017

Yunxin Chen

15

1 reference

Europe PubMed Central

5 October 2017

Feng Zhou

16

1 reference

Europe PubMed Central

5 October 2017

Weihan Zhang

17

1 reference

Europe PubMed Central

5 October 2017

Weiguo Qing

18

1 reference

Europe PubMed Central

5 October 2017

Weiguo Su

19

1 reference

Europe PubMed Central

5 October 2017

language of work or name

0 references

publication date

19 April 2017

1 reference

Europe PubMed Central

5 October 2017

1 reference

Europe PubMed Central

5 October 2017

8

1 reference

Europe PubMed Central

5 October 2017

31

1 reference

Europe PubMed Central

5 October 2017

50832-50844

1 reference

Europe PubMed Central

5 October 2017

Integrated genomic characterization of oesophageal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Cancer statistics in China, 2015.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Global cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Genomic and molecular characterization of esophageal squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Oesophageal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Epidermal growth factor receptor expression in esophageal adenocarcinoma: relationship with tumor stage and survival after esophagectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Identification of EGFR mutations in esophageal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

6 June 2018

Combination of cetuximab with radio-chemotherapy in patients with esophageal cancer: less is more!

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

19 August 2018

Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

19 August 2018

Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

19 August 2018

Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

19 August 2018

Hematoxylin and Eosin Staining of Tissue and Cell Sections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5584209

2 December 2018

Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50) values

1 reference

https://pubmed.ncbi.nlm.nih.gov/28881608

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/28881608

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.18632/ONCOTARGET.17243

1 reference

Europe PubMed Central

5 October 2017

1 reference

Europe PubMed Central

5 October 2017

1 reference

Europe PubMed Central

5 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41612476&oldid=1925072862"